| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Emergent BioSolutions (NYSE:EBS) reported its Q4 earnings results on Wednesday, March 6, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
Emergent BioSolutions missed estimated earnings by -305.0%, reporting an EPS of $-0.77 versus an estimate of $-0.19.
Revenue was down $54.10 million from the same period last year.
Last quarter the company missed on EPS by $0.65 which was followed by a 3.0% drop in the share price the next day.
Here's a look at Emergent BioSolutions's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.22 | -0.47 | -1.24 | 0.04 |
| EPS Actual | -0.87 | -1.06 | -3.17 | -0.31 |
| Revenue Estimate | 237.43M | 217.03M | 143.28M | 296.62M |
| Revenue Actual | 270.50M | 337.90M | 165.10M | 330.70M |
To track all earnings releases for Emergent BioSolutions visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: EBS
